Aethlon Medical has received approval from India's Drug Controller General to initiate a phase 1 trial of its Hemopurifier® in patients with solid tumors, as of this Thursday. The trial will focus on those undergoing anti-PD-1 checkpoint inhibitor therapy, such as Keytruda® or Opdivo®. The company's goal is to improve response rates by integrating Hemopurifier treatment with these inhibitors that target PD-1 proteins.
According to InvestingPro data, Aethlon Medical has a market capitalization of 23.13 billion USD, with a P/E ratio of 9.12, indicating a potentially undervalued stock. The company has also shown a solid performance, with a revenue growth of 25.2% in the last twelve months (LTM2023.Q2), and a gross profit margin of 54.01%.
A preliminary internal in vitro study will be conducted to assess the efficacy of Hemopurifier against PD-1 proteins. This will precede an extensive basket oncology trial for over 25 different types of cancer, with Aethlon aiming for regulatory approval. The trials are set to take place in India, including at Medanta Medicity Hospital, and Australia.
InvestingPro tips reveal that Aethlon operates with a moderate level of debt and its liquid assets exceed short-term obligations, suggesting financial stability. Moreover, the company has a history of maintaining its dividend payments for 31 consecutive years, demonstrating a commitment to rewarding its shareholders.
The Australian trials are facilitated by NAMSA and supported by the country's R&D tax incentives rebate program. This multi-national approach is part of Aethlon's broader strategy to validate Hemopurifier's potential in various medical fields.
In addition to its cancer trials, Aethlon is investigating Hemopurifier's potential to enhance organ transplantation outcomes by mitigating complications such as viral infection and rejection. This research aligns with their ongoing studies into cancer and COVID-19 treatments.
For their research coverage, the company receives an annual fee of up to $40,000. As Aethlon Medical continues its investigations into the potential applications of hemopurifiers, it remains committed to exploring innovative solutions for cancer treatment and beyond.
For more in-depth analysis and tips, consider subscribing to InvestingPro, which offers a wealth of additional tips and metrics about Aethlon and other companies. Find out more here.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.